Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2022 - 2025)

Taysha Gene Therapies' Total Non-Current Liabilities history spans 4 years, with the latest figure at $83.2 million for Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities rose 59.12% year-over-year to $83.2 million; the TTM value through Jun 2025 reached $83.2 million, up 59.12%, while the annual FY2024 figure was $87.5 million, 9.03% down from the prior year.
  • Total Non-Current Liabilities for Q2 2025 was $83.2 million at Taysha Gene Therapies, up from $82.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $241.1 million in Q3 2023 and bottomed at $52.3 million in Q2 2024.
  • The 4-year median for Total Non-Current Liabilities is $96.4 million (2022), against an average of $104.8 million.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 150.03% in 2023 before it crashed 54.42% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $121.2 million in 2022, then fell by 20.61% to $96.2 million in 2023, then fell by 9.03% to $87.5 million in 2024, then dropped by 4.94% to $83.2 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Total Non-Current Liabilities are $83.2 million (Q2 2025), $82.1 million (Q1 2025), and $87.5 million (Q4 2024).